Zaloguj się

Gotowe bibliografie tematyczne / IL-6 / Artykuły w czasopismach

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: IL-6.

Artykuły w czasopismach na temat „IL-6”

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 25 maja 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „IL-6”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Toshiro, Shimamura, Taki Shinsuke, Honda Hideo, Yokota Masataka, Ito Satoru i Takahara Yoshiyuki. "Analysis of interleukin 6 (IL-6)/IL-6 receptor system using monoclonal anti-IL-6 antibodies". Molecular Immunology 28, nr 11 (listopad 1991): 1155–61. http://dx.doi.org/10.1016/0161-5890(91)90001-z.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

TAMM, IGOR. "IL-6". Annals of the New York Academy of Sciences 557, nr 1 (28.06.2008): 478–89. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24040.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Gaillard, O. "Interleukine 6 (IL-6)". Immuno-analyse & Biologie Spécialisée 17, nr 3 (czerwiec 2002): 140–42. http://dx.doi.org/10.1016/s0923-2532(02)01191-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Matsuda, Tadashi, i Toshio Hirano. "Interleukin 6 (IL-6)". Biotherapy 2, nr 4 (październik 1990): 363–73. http://dx.doi.org/10.1007/bf02170085.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

Hansen, MB, M. Svenson, M. Diamant, C. Ross i K. Bendtzen. "Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements [letter]". Blood 85, nr 4 (15.02.1995): 1145. http://dx.doi.org/10.1182/blood.v85.4.1145.bloodjournal8541145.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Usha, Prof. "IL-4 and IL-6 in Bronchial Asthma Does IL-6 Plays More Important Role than IL-4? A Preliminary Study". Journal of Medical Science And clinical Research 05, nr 04 (18.04.2017): 20446–50. http://dx.doi.org/10.18535/jmscr/v5i4.115.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Van Wagoner, Nicholas J., Jae-Wook Oh, Pavle Repovic i Etty N. Benveniste. "Interleukin-6 (IL-6) Production by Astrocytes: Autocrine Regulation by IL-6 and the Soluble IL-6 Receptor". Journal of Neuroscience 19, nr 13 (1.07.1999): 5236–44. http://dx.doi.org/10.1523/jneurosci.19-13-05236.1999.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Baran, Paul, Rebecca Nitz, Joachim Grötzinger, Jürgen Scheller i Christoph Garbers. "Minimal Interleukin 6 (IL-6) Receptor Stalk Composition for IL-6 Receptor Shedding and IL-6 Classic Signaling". Journal of Biological Chemistry 288, nr 21 (5.04.2013): 14756–68. http://dx.doi.org/10.1074/jbc.m113.466169.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Jostock, Thomas, Guido Blinn, Christoph Renné, Karl-Josef Kallen, Stefan Rose-John i Jürgen Müllberg. "Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6". Journal of Immunological Methods 223, nr 2 (marzec 1999): 171–83. http://dx.doi.org/10.1016/s0022-1759(98)00218-x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Pooran, Nakechand, Anant Indaram, Pankaj Singh i Simmy Bank. "Cytokines (IL-6, IL-8, TNF)". Journal of Clinical Gastroenterology 37, nr 3 (wrzesień 2003): 263–66. http://dx.doi.org/10.1097/00004836-200309000-00013.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Nishimoto, Norihiro. "6. IL-6 Inhibitors for Treatment of Rheumatoid Arthritis". Nihon Naika Gakkai Zasshi 97, nr 10 (2008): 2413–17. http://dx.doi.org/10.2169/naika.97.2413.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

12

SNICK, JACQUES, JEAN-CHRISTOPHE RENAULD, RICHARD J. SIMPSON, CATHERINE UYTTENHOVE i ANNE VINK. "Mouse IL-6". Annals of the New York Academy of Sciences 557, nr 1 (28.06.2008): 206–14. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24014.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Hodgson, John. "Patenting IL-6". Nature Biotechnology 10, nr 1 (styczeń 1992): 16. http://dx.doi.org/10.1038/nbt0192-16.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

McInnes, Iain. "Considering IL-6". Considerations in Medicine 2, nr 1 (listopad 2018): 1. http://dx.doi.org/10.1136/conmed-2018-000006.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Metz, Silke, Monique Wiesinger, Michael Vogt, Heike Lauks, Günther Schmalzing, Peter C. Heinrich i Gerhard Müller-Newen. "Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP". Journal of Biological Chemistry 282, nr 2 (3.11.2006): 1238–48. http://dx.doi.org/10.1074/jbc.m606885200.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

De Benedetti, F., M. Massa, P. Pignatti, S. Albani, D. Novick i A. Martini. "Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis." Journal of Clinical Investigation 93, nr 5 (1.05.1994): 2114–19. http://dx.doi.org/10.1172/jci117206.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Nakajima, Ayako. "2. IL-6 Inhibitor". Nihon Naika Gakkai Zasshi 100, nr 10 (2011): 2972–78. http://dx.doi.org/10.2169/naika.100.2972.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Szot, Patricia, Allyn Franklin, Dianne P. Figlewicz, Timothy Petru Beuca, Kristin Bullock, Kim Hansen, William A. Banks, Murray A. Raskind i Elaine R. Peskind. "Multiple lipopolysaccharide (LPS) injections alter interleukin 6 (IL-6), IL-7, IL-10 and IL-6 and IL-7 receptor mRNA in CNS and spleen". Neuroscience 355 (lipiec 2017): 9–21. http://dx.doi.org/10.1016/j.neuroscience.2017.04.028.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Baran, Paul, Selina Hansen, Georg H. Waetzig, Mohammad Akbarzadeh, Larissa Lamertz, Heinrich J. Huber, M. Reza Ahmadian, Jens M. Moll i Jürgen Scheller. "The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling". Journal of Biological Chemistry 293, nr 18 (20.03.2018): 6762–75. http://dx.doi.org/10.1074/jbc.ra117.001163.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Uchiyama, Yasushi, Hiroto Yoshida, Nobuo Koike, Naohiko Hayakawa, Atsuko Sugita, Takashi Nishimura i Masahiko Mihara. "Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production". International Immunopharmacology 8, nr 11 (listopad 2008): 1595–601. http://dx.doi.org/10.1016/j.intimp.2008.07.002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

HIRANO, TOSHIO. "Interleukin 6 (IL-6) and disease." Japanese Journal of Clinical Immunology 13, nr 5 (1990): 444–45. http://dx.doi.org/10.2177/jsci.13.444.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Schöbitz, Bernd, Gita Pezeshki, Thomas Pohl, Ulrike Hemmann, Peter C. Heinrich, Florian Holsboer i Johannes M. H. M. Reul. "Soluble interleukin‐6 (IL‐6) receptor augments central effects of IL‐6 in vivo". FASEB Journal 9, nr 8 (maj 1995): 659–64. http://dx.doi.org/10.1096/fasebj.9.8.7768358.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Hansen, Morten Bagge, Morten Svenson, Kathrine Abell, Kiyoshi Yasukawa, Marcus Diamant i Klaus Bendtzen. "Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors". European Journal of Immunology 25, nr 2 (luty 1995): 348–54. http://dx.doi.org/10.1002/eji.1830250207.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Baiocchi, Marta, Isabella Marcucci, Stefan Rose-John, Ottaviano Serlupi-Crescenzi i Mauro Biffoni. "AN IL-6/IL-6 SOLUBLE RECEPTOR (IL-6R) HYBRID PROTEIN (H-IL-6) INDUCES EPO-INDEPENDENT ERYTHROID DIFFERENTIATION IN HUMAN CD34+CELLS". Cytokine 12, nr 9 (wrzesień 2000): 1395–99. http://dx.doi.org/10.1006/cyto.2000.0723.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Rose-John, Stefan. "IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6". International Journal of Biological Sciences 8, nr 9 (2012): 1237–47. http://dx.doi.org/10.7150/ijbs.4989.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Suzuki, H., H. Takemura, K. Yoshizaki, Y. Koishihara, Y. Ohsugi, A. Okano, Y. Akiyama, T. Tojo, T. Kishimoto i H. Kashiwagi. "IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis." Journal of Immunology 152, nr 2 (15.01.1994): 935–42. http://dx.doi.org/10.4049/jimmunol.152.2.935.

Pełny tekst źródła

Streszczenie:

Abstract Anti-IL-6 IgG autoantibodies, often found in sera from patients with systemic sclerosis, may increase to the level sufficient to bind significant amounts of IL-6 in serum. In our study of the role of anti-IL-6 autoantibodies in serum, we found that some sera with the autoantibodies possessed considerably higher IL-6 levels (more than 100 pg/ml) compared with most of sera without the autoantibodies. Size-exclusion HPLC of the sera with these autoantibodies demonstrated that a significant part of the serum IL-6 activity was attributable to circulating IL-6-anti-IL-6 autoantibody complexes. Gel filtration of IL-6-anti-IL-6 IgG complexes made in vitro by incubation of rIL-6 and IgG purified from the autoantibody-positive sera demonstrated that the complexes at 200 to 250 kDa were dominant ones and that IL-6 bound to the autoantibodies retained more than 60% of the original IL-6 activity. Moreover, IL-6-anti-IL-6 autoantibody complexes were shown to bind to recombinant soluble IL-6 receptors. Estimated affinity of anti-IL-6 IgG autoantibodies from two patients was fairly high (4.2 x 10(9) to 3.3 x 10(10) L/M). Therefore, the retention of IL-6 activity by IL-6-anti-IL-6 autoantibody complexes may be explained by intact receptor-binding sites on the autoantibody-bound IL-6 molecules. Taken together, these results suggest that the properties of anti-IL-6 autoantibodies are consistent with a potential role as specific carriers for IL-6 in the circulation.

Style APA, Harvard, Vancouver, ISO itp.

27

Park, Sung Tae. "상대적 운동 강도가 형철 IL-2, IL-6 농도에 미치는 효과". Journal of Sport and Leisure Studies 23 (31.05.2005): 319–27. http://dx.doi.org/10.51979/kssls.2005.05.23.319.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Tanaka, Toshio, Masashi Narazaki i Tadamitsu Kishimoto. "Interleukin (IL-6) Immunotherapy". Cold Spring Harbor Perspectives in Biology 10, nr 8 (4.08.2017): a028456. http://dx.doi.org/10.1101/cshperspect.a028456.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

Hoene, Miriam, Louise Fritsche, Rainer Lehmann, Anita M. Hennige, Hans-Ulrich Häring, Erwin Schleicher i Cora Weigert. "Running without IL-6". Medicine & Science in Sports & Exercise 40, Supplement (maj 2008): S192. http://dx.doi.org/10.1249/01.mss.0000322290.16416.c4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Rose-John, Stefan, i Markus F. Neurath. "IL-6 trans-Signaling". Immunity 20, nr 1 (styczeń 2004): 2–4. http://dx.doi.org/10.1016/s1074-7613(04)00003-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

31

Gutierrez, G., G. Junovich, V. Dubinsky i T. Gentile. "IL-6 in reproduction". Journal of Reproductive Immunology 75, nr 1 (sierpień 2007): A4—A5. http://dx.doi.org/10.1016/j.jri.2007.06.007.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Upadhyaya, Smitha, Vinitha Kadamkode, Rafi Mahammed, Chandraprabha Doraiswami i Gautam Banerjee. "Adiponectin and IL-6". Adipocyte 3, nr 1 (8.10.2013): 39–45. http://dx.doi.org/10.4161/adip.26553.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

33

Malberg, Kurt. "Psychostress und IL-6". Allergo Journal 20, nr 3 (kwiecień 2011): 134. http://dx.doi.org/10.1007/bf03362453.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

34

Pizzi, Marina, Ilenia Sarnico, Flora Boroni, Marina Benarese, Michel Dreano, Gianni Garotta, Alessandra Valerio i PierFranco Spano. "Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices". Molecular and Cellular Neuroscience 25, nr 2 (luty 2004): 301–11. http://dx.doi.org/10.1016/j.mcn.2003.10.022.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Ding, W., L. L. Stohl, V. Isak, J. A. Wagner, Z. Bulmer i R. D. Granstein. "006 IL-6 enhances IL-6 expression by epidermal langerhans cells (LCs)". Journal of Investigative Dermatology 142, nr 8 (sierpień 2022): S1. http://dx.doi.org/10.1016/j.jid.2022.05.060.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

36

Potere, Nicola, Alberto Batticciotto, Alessandra Vecchié, Ettore Porreca, Antonella Cappelli, Antonio Abbate, Francesco Dentali i Aldo Bonaventura. "The role of IL-6 and IL-6 blockade in COVID-19". Expert Review of Clinical Immunology 17, nr 6 (27.05.2021): 601–18. http://dx.doi.org/10.1080/1744666x.2021.1919086.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

Müllberg, Jürgen, Till Geib, Thomas Jostock, Susanne H. Hoischen, Petra Vollmer, Nicole Voltz, David Heinz, Peter R. Galle, Mariam Klouche i Stefan Rose-John. "IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-6". Journal of Immunology 164, nr 9 (1.05.2000): 4672–77. http://dx.doi.org/10.4049/jimmunol.164.9.4672.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Nanki, Toshihiro. "Advances of treatment with IL-6/IL-6 receptor inhibitors for RA". Proceedings for Annual Meeting of The Japanese Pharmacological Society WCP2018 (2018): SY61–2. http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_sy61-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Suzuki, H., K. Yasukawa, T. Saito, M. Anzai, R. Goitsuka, A. Hasegawa, Y. Ohsugi, T. Taga i T. Kishimoto. "Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo". Immunology Letters 30, nr 1 (wrzesień 1991): 17–22. http://dx.doi.org/10.1016/0165-2478(91)90083-m.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Li, Yan, Carl-Magnus Bäckesjö, Lars-Arne Haldosén i Urban Lindgren. "IL-6 receptor expression and IL-6 effects change during osteoblast differentiation". Cytokine 43, nr 2 (sierpień 2008): 165–73. http://dx.doi.org/10.1016/j.cyto.2008.05.007.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Osborne, Julie, Patrick S. Moore i Yuan Chang. "KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways". Human Immunology 60, nr 10 (październik 1999): 921–27. http://dx.doi.org/10.1016/s0198-8859(99)00083-x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Gadient, R. A., i U. Otten. "Postnatal expression of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) mRNAs in rat sympathetic and sensory ganglia". Brain Research 724, nr 1 (czerwiec 1996): 41–46. http://dx.doi.org/10.1016/0006-8993(96)00264-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Gadient, R. A., A. Lachmund, K. Unsicker i U. Otten. "Expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat adrenal medulla". Neuroscience Letters 194, nr 1-2 (lipiec 1995): 17–20. http://dx.doi.org/10.1016/0304-3940(95)11708-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

Hoyland, Judith A., A. J. Freemont i P. T. Sharpe. "Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in paget's disease". Journal of Bone and Mineral Research 9, nr 1 (3.12.2009): 75–80. http://dx.doi.org/10.1002/jbmr.5650090111.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Berndt, J. D. "IL-11 Trumps IL-6 in Gastrointestinal Cancer". Science Signaling 6, nr 291 (3.09.2013): ec208-ec208. http://dx.doi.org/10.1126/scisignal.2004692.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Sabite;KARATAN, KAÇAR. "AMİLOİDOZİSDE SERUM IL-6, IL-1a, TNFa DÜZEYLERİ". Ankara Üniversitesi Tıp Fakültesi Mecmuası 52, nr 4 (1999): 1. http://dx.doi.org/10.1501/tipfak_0000000401.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Brunssen, Susan H., Sheryl S. Moy, Arrel D. Toews, Christopher A. McPherson i G. Jean Harry. "Interleukin-6 (IL-6) receptor/IL-6 fusion protein (Hyper IL-6) effects on the neonatal mouse brain: Possible role for IL-6 trans-signaling in brain development and functional neurobehavioral outcomes". Brain, Behavior, and Immunity 27 (styczeń 2013): 42–53. http://dx.doi.org/10.1016/j.bbi.2012.08.017.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Inoue, K., H. Sugiyama, H. Ogawa, T. Yamagami, T. Azuma, Y. Oka, H. Miwa, K. Kita, A. Hiraoka i T. Masaoka. "Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia". Blood 84, nr 8 (15.10.1994): 2672–80. http://dx.doi.org/10.1182/blood.v84.8.2672.2672.

Pełny tekst źródła

Streszczenie:

Abstract Expression patterns of interleukin-6 (IL-6), IL-6 receptor (IL-6R), and gp130 genes in 39 patients with acute myeloid leukemia (AML), in 23 patients with acute lymphoblastic leukemia (ALL), and in 7 patients with acute mixed lineage leukemia (AMLL) were studied by quantitative reverse transcriptase-polymerase chain reaction. Significant levels of IL-6 were expressed in 8 (21%) of 39 AML patients and in 2 (29%) of 7 AMLL patients, whereas in ALL, the expression of IL-6 was almost negligible. IL-6R was expressed in all patients with AML and AMLL, whereas only half of ALL patients expressed low levels of IL-6R as compared with those with AML and AMLL. However, gp130 was ubiquitously expressed in all the leukemia patients, and there was no significant difference in gp130 expression among AML, ALL, and AMLL. Significant correlation was observed between the expression of IL-6R and gp130 in AML. When tested for in vitro response to IL-6, the leukemic cells from 3 of 7 AML, none of 3 ALL, and both of 2 AMLL patients significantly responded to IL-6, showing the correlation between the expression levels of IL-6R and gp130 and the responsiveness of leukemic cells to IL-6. These results showed that quantitation of IL-6R and gp130 expression by reverse transcriptase-polymerase chain reaction is useful for the rapid prediction of the responsiveness of leukemic cells to IL- 6, especially in cases of administration of IL-6.

Style APA, Harvard, Vancouver, ISO itp.

49

Inoue, K., H. Sugiyama, H. Ogawa, T. Yamagami, T. Azuma, Y. Oka, H. Miwa, K. Kita, A. Hiraoka i T. Masaoka. "Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia". Blood 84, nr 8 (15.10.1994): 2672–80. http://dx.doi.org/10.1182/blood.v84.8.2672.bloodjournal8482672.

Pełny tekst źródła

Streszczenie:

Expression patterns of interleukin-6 (IL-6), IL-6 receptor (IL-6R), and gp130 genes in 39 patients with acute myeloid leukemia (AML), in 23 patients with acute lymphoblastic leukemia (ALL), and in 7 patients with acute mixed lineage leukemia (AMLL) were studied by quantitative reverse transcriptase-polymerase chain reaction. Significant levels of IL-6 were expressed in 8 (21%) of 39 AML patients and in 2 (29%) of 7 AMLL patients, whereas in ALL, the expression of IL-6 was almost negligible. IL-6R was expressed in all patients with AML and AMLL, whereas only half of ALL patients expressed low levels of IL-6R as compared with those with AML and AMLL. However, gp130 was ubiquitously expressed in all the leukemia patients, and there was no significant difference in gp130 expression among AML, ALL, and AMLL. Significant correlation was observed between the expression of IL-6R and gp130 in AML. When tested for in vitro response to IL-6, the leukemic cells from 3 of 7 AML, none of 3 ALL, and both of 2 AMLL patients significantly responded to IL-6, showing the correlation between the expression levels of IL-6R and gp130 and the responsiveness of leukemic cells to IL-6. These results showed that quantitation of IL-6R and gp130 expression by reverse transcriptase-polymerase chain reaction is useful for the rapid prediction of the responsiveness of leukemic cells to IL- 6, especially in cases of administration of IL-6.

Style APA, Harvard, Vancouver, ISO itp.

50

Nemunaitis, J., DF Andrews, DY Mochizuki, MB Lilly i JW Singer. "Human marrow stromal cells: response to interleukin-6 (IL-6) and control of IL-6 expression". Blood 74, nr 6 (1.11.1989): 1929–35. http://dx.doi.org/10.1182/blood.v74.6.1929.1929.

Pełny tekst źródła

Streszczenie:

Abstract Production of interleukin-6 (IL-6) by marrow stromal cells from human long-term marrow cultures and from stromal cells transformed with simian virus 40 was examined. As with other cultured mesenchymal cells, unstimulated stromal cells produced undetectable amounts of IL-6 mRNA when assayed by Northern blots. However, within 30 minutes after exposure of transformed marrow stromal cells to the inflammatory mediators, recombinant human interleukin-1 alpha (IL-1 alpha) or recombinant human tumor necrosis factor alpha (TNF alpha), significant increases in IL-6 expression were observed. The time course of IL-6 mRNA upregulation in transformed marrow stromal cells with IL-1 alpha and TNF alpha differed: The maximal response to TNF alpha was observed at 30 minutes whereas that to IL-1 alpha occurred at 8 hours. Although IL-6 at a concentration of 500 U/mL was inhibitory to adherent transformed marrow stromal cell proliferation, a concentration- dependent stimulation of anchorage-independent colony growth was observed when the cells were plated in semisolid medium with IL-6. The stromal cell colony-stimulating effect of IL-6 was abrogated by a neutralizing antibody to IL-6. Moreover, the heteroserum with anti-IL-6 activity and two anti-IL-6 monoclonal antibodies partially blocked autonomous and IL-1 alpha-induced colony formation, suggesting that colony formation by transformed marrow stromal cells may require IL-6. Clonal-transformed stromal cell lines were derived from the anchorage- independent stromal cell colonies. Both IL-6 mRNA and protein were constitutively produced at high levels. The addition of IL-6 to either long-term marrow culture adherent cells or transformed marrow stromal cells downregulated the expression of collagen I, a major stromal cell matrix protein. Thus, IL-6 affects proliferation of stromal cells and influences their production of extracellular matrix, suggesting that IL- 6 may have indirect as well as direct influences on hematopoietic cell proliferation.

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!